Aardvark Therapeutics, Inc. 10-Q — AI Bull & Bear Analysis

The Q1 2026 filing reveals a company at a critical inflection point, balancing high-potential science against emerging safety and financial pressures. The voluntary pause of the HERO trial is the primary catalyst for investors, shifting the focus from immediate data readouts to the outcome of FDA collaborations. While the $91.2 million liquidity provides a temporary buffer, the widening net loss and the scale of future milestone payments create a race against time. Ultimately, the investment thesis hinges on whether the cardiac observations are a manageable hurdle or a fundamental flaw in the TAS2R mechanism. If the FDA allows a restart with modified protocols, Aardvark's unique approach to hunger suppression could offer a compelling alternative to the GLP-1 market. However, the current lack of revenue and the acceleration of expenses leave little room for error in clinical execution.